– USA, MA – Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Corey N. Fishman to its Board of Directors effective September 22, 2016. Mr. Fishman currently serves as Chief Executive Officer of Iterum Therapeutics Limited, a clinical-stage pharmaceutical company developing differentiated anti-infectives for combatting multi-drug resistant pathogens.
“We are very pleased to welcome Corey to Momenta’s Board of Directors at this important stage in our company’s development and growth,” said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. “Corey is a seasoned pharmaceutical industry executive with a unique combination of commercial, operations, finance and business development expertise. His extensive experience will be a great asset to our Company as we continue to advance our pipeline of complex generic, biosimilar and novel drug candidates toward commercialization.”
Mr. Fishman has served as Chief Executive Officer of Iterum Therapeutics Limited since its founding in late 2015. Previously he served as Chief Financial and Chief Operating Officer of Durata Therapeutics, Inc. where he managed a successful IPO and secondary offering, and led the negotiation and sale of the Company to Actavis plc. Prior to Durata, Mr. Fishman served as Chief Financial Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus Company, and served in several leadership roles, including Chief Financial Officer, at MedPointe Healthcare, Inc. Mr. Fishman holds a BA in Economics from the University of Illinois at Urbana-Champaign and an MSM in Finance from the Krannert School of Management at Purdue University.
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.